Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

Item
http://www.wikidata.org/entity/Q27686800
Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of ImmunotherapyExploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell VaccinesTolerogenic Dendritic Cells for Regulatory T Cell Induction in ManRestoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and PreventionAntigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumorsA phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatmentTranscriptional Targeting of Mature Dendritic Cells with Adenoviral Vectors via a Modular Promoter System for Antigen Expression and Functional Manipulation.Understanding dendritic cell immunotherapy in ovarian cancer.Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.CD1a+ and CD83+ Langerhans cells are reduced in lower lip squamous cell carcinoma.Update in the Therapy of Advanced Neuroendocrine Tumors.Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.In silico prediction of cancer immunogens: current state of the art.
P2860

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

Item
http://www.wikidata.org/entity/Q27686800
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Rationale for a Multimodality ...... ll-Based Cancer Immunotherapy.
@ast
Rationale for a Multimodality ...... ll-Based Cancer Immunotherapy.
@en
Rationale for a Multimodality ...... ll-Based Cancer Immunotherapy.
@nl
type
label
Rationale for a Multimodality ...... ll-Based Cancer Immunotherapy.
@ast
Rationale for a Multimodality ...... ll-Based Cancer Immunotherapy.
@en
Rationale for a Multimodality ...... ll-Based Cancer Immunotherapy.
@nl
prefLabel
Rationale for a Multimodality ...... ll-Based Cancer Immunotherapy.
@ast
Rationale for a Multimodality ...... ll-Based Cancer Immunotherapy.
@en
Rationale for a Multimodality ...... ll-Based Cancer Immunotherapy.
@nl
P1433
P1476
P2093
P2860
P304
P31
P3181
P356
P478
P577
P5875
P698
P921
P932
P3181
P356
P1433
P1476
Rationale for a Multimodality ...... ll-Based Cancer Immunotherapy.
@en
P2093
P2860
P304
P31
P3181
P356
P478
P577
P5875
P698
P921
P932